Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 20 of 20

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract May 2006

The Preservative Effects of "Antibiotic Concentration" and "Addition of BAK" on the Time–Kill Comparison of Moxifloxacin and Gatifloxacin

R.P. Kowalski; B.R. Kowalski; P.P. Thompson; E.G. Romanowski; F.S. Mah; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):1888.

ARVO Annual Meeting Abstract May 2006

Vigamox® (0.5% Moxifloxacin) Is Effective in Reducing Staphylococcus aureus Colony Counts in a NZW Rabbit Endophthalmitis Model

E.G. Romanowski; R.P. Kowalski; K.A. Yates; F.S. Mah; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):1899.

ARVO Annual Meeting Abstract May 2006

Benzalkonium Chloride (BAK) Significantly Enhances the Antibacterial Efficacy of Gatifloxacin in the Staphylococcus Aureus NZW Rabbit Keratitis Model

F.S. Mah; E.G. Romanowski; R.P. Kowalski; K.A. Yates; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):1905.

ARVO Annual Meeting Abstract May 2006

Linezolid and Daptomycin: Future Ophthalmic Antibiotics?

K.A. Yates; R.P. Kowalski; E.G. Romanowski; F.S. Mah; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):1925.

ARVO Annual Meeting Abstract May 2006

Transcriptomic Responses of Human Conjunctival Epithelial Cells to Adenovirus Serotype 19 Infection

S.A. Harvey; E.G. Romanowski; K.A. Yates; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):3047.

ARVO Annual Meeting Abstract May 2005

A Novel Topical Antiviral Agent, PCL–016 (Picolinic Acid), Inhibits Adenovirus Replication in the Ad5/NZW Rabbit Ocular Model

E.G. Romanowski; K.A. Yates; R.P. Kowalski; F.S. Mah; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1024.

ARVO Annual Meeting Abstract May 2005

Topical N–Chlorotaurine (NCT), an Endogenous Microbicidal Oxidant, Inhibits Adenovirus Replication in the Ad5/NZW Rabbit Ocular Model

K.A. Yates; E.G. Romanowski; B. Teuchner; M. Nagl; W. Gottardi; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1025.

ARVO Annual Meeting Abstract May 2005

A Comparison of Zymar (Gatifloxacin 03%) To Ciloxan (Ciprofloxacin 03%) and Fortified Tobramycin in the Treatment of Experimental Pseudomonas Aeruginosa and Serratia Marcescens Keratitis in the NZW Rabbit Model

F.S. Mah; R.P. Kowalski; E.G. Romanowski; K.A. Yates; B.R. Kowalski; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):2771.

ARVO Annual Meeting Abstract May 2005

Intravitreal VigamoxTM (0.5% Moxifloxacin) Is Non–Toxic and Effective in Preventing Endophthalmitis in a NZW Rabbit Model

R.P. Kowalski; E.G. Romanowski; F.S. Mah; K.A. Yates; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):2773.

ARVO Annual Meeting Abstract May 2005

In vitro Comparison of Antibiotic Resistance From 1996 to 2004 for Antibiotics Used for Conjunctivitis Therapy

B.R. Kowalski; R.P. Kowalski; E.G. Romanowski; F.S. Mah; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):2780.

ARVO Annual Meeting Abstract May 2005

Human CAP–37, a Cationic Protein, Demonstrates Direct Antiviral Activity against Adenovirus Types 3 and 5 and Herpes Simplex Virus in vitro

Y. Gordon; E.G. Romanowski; K.A. Yates; H.A. Pereira

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):2797.

ARVO Annual Meeting Abstract May 2004

Gatifloxacin (ZymarTM) Can Be Effective In Comparison To Vancomycin And Cefazolin For Treating Gatifloxacin–Resistant Staphylococcus aureus Keratitis in a NZW Rabbit Model

R.P. Kowalski; F.S. Mah; E.G. Romanowski; K.A. Yates; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):4903.

ARVO Annual Meeting Abstract May 2004

Comparison of a New Topical Fluoroquinolone, Gatifloxacin (ZymarTM), with Levofloxacin (QixinTM) and Ciprofloxacin (CiloxanTM) in the Treatment of Fluoroquinolone–Resistant Staphylococcus aureus Keratitis in a NZW Rabbit Model.

F.S. Mah; E.G. Romanowski; K.A. Yates; R.P. Kowalski; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):4982.

ARVO Annual Meeting Abstract May 2004

Topical NMSO3 Inhibits Adenovirus Replication in the Ad5/NZW Rabbit Ocular Model.

E.G. Romanowski; T.L. Bowlin; K.A. Yates; F.S. Mah; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):1657.

ARVO Annual Meeting Abstract May 2004

Human Cathelicidin (LL–37/hCAP–18) Demonstrates Direct Antiviral Activity Against Adenovirus and Herpes Simplex Virus In Vitro.

Y. Gordon; E.G. Romanowski; K.A. Yates; A.M. McDermott

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):2256.

ARVO Annual Meeting Abstract May 2003

The Prevention of Bacterial Endophthalmitis by Topical Moxifloxacin in a Rabbit Prophylaxis Model

R.P. Kowalski; E.G. Romanowski; F.S. Mah; K.A. Yates; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):1467.

ARVO Annual Meeting Abstract May 2003

The In Vitro Evaluation of the Ophthalmic Fluoroquinolones Against Bacterial Conjunctivitis Isolates

K.A. Yates; R.P. Kowalski; E.G. Romanowski; F.S. Mah; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):2118.

ARVO Annual Meeting Abstract May 2003

Diffuse Lamellar Keratitis (DLK): Can Fluoroquinolones Worsen DLK?

F.S. Mah; D.K. Dhaliwal; E.G. Romanowski; K.A. Yates; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):2662.

ARVO Annual Meeting Abstract May 2003

Adenovirus Infection of Human Conjunctival Cells: Insights into the Innate Immune Response by Microarray Analysis

Y.J. Gordon; E.G. Romanowski; S.A. Harvey

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):4186.

ARVO Annual Meeting Abstract May 2003

Human Conjunctival Defensins Demonstrate Direct Antiviral Activity against Adenovirus In Vitro

E.G. Romanowski; K.A. Yates; Y.J. Gordon

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):4648.

Advertisement